Aurobindo Pharma Ltd

GST ITC reversal matter

• Appellate Joint Commissioner upholds reversal of ITC claim for FY2020-21.
• Total disputed amount Rs 4,60,28,908; interest Rs 1,78,19,409 and penalty Rs 25,64,500.
• ITC reversal relates to excess ITC in GSTR-3B versus GSTR-2A.
• Order received 28 Sep 2026; order dated 28 Feb 2025.
• Company to file appeal before GST Appellate Tribunal; no material impact.

GST ITC reversal details

• Appellate Joint Commissioner ST Hyderabad confirmed ITC reversal for FY2020-21.
• Total disputed amount: Rs 4,60,28,908 including interest and penalties.
• Breakdown: CGST 81,04,008; SGST 81,04,008; IGST 94,36,983; interest 1,78,19,409; penalty 25,64,500.
• Order date: 28 September 2026; received 28 September 2026 16:51 Hrs.
• Company intends to file appeal before GST Appellate Tribunal (APL 04 No. ZD360926066348S).
• There is no material impact on financials or operations per the filing.

Meeting Details

• Date and time: September 24, 2026, 02:30 PM to 03:30 PM IST.
• Meeting type and mode: group meeting, physical in Hyderabad.
• Event/conference name: JP Morgan Healthcare Trip - Hyderabad.
• Key company participants: company officials (management) attending.
• Purpose: investor/analyst meeting with JP Morgan Healthcare Trip Hyderabad.

US FDA inspection outcome

• US FDA inspected Unit-II of Apitoria Pharma Private Limited (subsidiary) Sep 7–15, 2026.
• Inspection concluded with one procedural observation.
• Company to respond to FDA within the stipulated timeline.
• No other issues reported; commitment to robust quality and compliance.
• No financial implications disclosed; stock exchanges to be informed of developments.

Key developments

• USFDA final approval to manufacture and market Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg and 80 mcg.
• First MDI product for Aurobindo, enabling expansion into complex respiratory therapies.
• Manufacturing at Raleigh facility; Aurolife Pharma LLC subsidiary.
• Launch expected in upcoming quarters.
• IQVIA estimates US market size US$301 million for 12 months ended July 2026.
• Cumulative USFDA ANDA approvals total 596, with 571 final and 25 tentative.

Target overview

• Target: A1 Biochem USA Inc, US-based contract research and development services company.
• Size: Initial share capital USD 1,000,000; 10,000 shares of USD 100 each.
• Ownership: 100% equity stake acquired via cash subscription.
• Related party: A1 Biochem USA Inc is wholly owned by A1 Biochem Labs India Pvt Ltd.
• Promoter interest: Promoters not interested in the transaction.
• Industry: Pharmaceuticals.
• Purpose: To undertake CRO services as part of A1 Biochem Group acquisition.
• Regulatory: No approvals required.
• Timeline: Not specified.
• Consideration: 100% cash subscription; USD 1,000,000.
• Background: Newly incorporated in USA; incorporation date Aug 27, 2026; CRO focus; no turnover history.

Target entity

• Target: A1 Biochem USA Inc, US-based pharma entity.
• Turnover: not applicable yet as business has not commenced.
• Newly incorporated; US presence for CRO operations.

Transaction details

• Related party: A1 Biochem USA Inc wholly owned by A1 Biochem Labs India Pvt Ltd.
• Promoters not interested in the transaction.
• Consideration: 100% cash subscription to share capital.
• Cost: USD 1,000,000 for 10,000 shares of USD 100 each.
• Shareholding: 100% acquired.
• Regulatory approvals: none required.
• Timeframe: completion not applicable.

Background

• Newly incorporated company; incorporation date Aug 27, 2026; US CRO setup.
• Last three years turnover: not available.
• Business: Contract Research and Development services.